NCT06900049View on ClinicalTrials.gov

Evaluation of the Safety, Tolerability, and Efficacy of LE051 in Patients With Duchenne Muscular Dystrophy

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 24, 2024

Primary Completion Date

September 20, 2026

Study Completion Date

December 31, 2026

Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
DRUG

LE051

LE051 dose escalation : dose 1 and dose 2.

Trial Locations (1)

200127

RECRUITING

Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

Shanghai Jiao Tong University School of Medicine

OTHER